Further, synthetic Nrf2 activators such as Bardoxolone, have demonstrated reduced glomerulosclerosis, interstitial fibrosis and inflammation through decreasing NF-κB activation in multiple rodent models of kidney disease [91,92,93,94]. This evidence concerns the gene NFE2L2 and kidney disorder.